Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab vs Watch and Wait in Untreated Low Tumor Burden Follicular Lymphoma
NCT07783594Phase 2Not yet recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2027
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab in follicular lymphoma (FL), sponsored by University of Texas MD Anderson Cancer Center. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
epcoritamab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07783594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07783594.